Elite in Richter Syndrome

Dr. John N. Allan

Hematology Oncology | Oncology | Hematology
Weill Medical College Of Cornell
520 E 70th St, 
New York, NY 
Offers Telehealth
16 Years of Experience
Elite in Richter Syndrome
Weill Medical College Of Cornell
520 E 70th St, 
New York, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

John Allan is a Hematologist Oncology specialist and an Oncologist in New York, New York. Dr. Allan has been practicing medicine for over 16 years and is rated as an Elite provider by MediFind in the treatment of Richter Syndrome. His top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Richter Syndrome, Bone Marrow Aspiration, and Splenectomy.

His clinical research consists of co-authoring 68 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 5 articles in the study of Richter Syndrome.

Graduate Year
2009
Specialties
Hematology Oncology
Oncology
Hematology
Hospital Affiliations
New York-Presbyterian Hospital
Hospital For Special Surgery
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health First
  • HMO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MetLife
  • PPO
MVP Health
  • EPO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VNS Health
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

WEILL MEDICAL COLLEGE OF CORNELL
520 E 70th St, New York, NY 10021

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM)
A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM)
Enrollment Status: Completed
Publish Date: October 26, 2024
Intervention Type: Drug
Study Drugs: BGB-3111 (Zanubrutinib), Ibrutinib
Study Phase: Phase 3
A Combined Phase 1/2 Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of TP-0903 in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)
A Combined Phase 1/2 Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of TP-0903 in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Terminated
Publish Date: November 09, 2023
Intervention Type: Drug, Combination product
Study Phase: Phase 1/Phase 2
A Phase II Study of Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia
A Phase II Study of Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia
Enrollment Status: Terminated
Publish Date: October 23, 2023
Intervention Type: Drug
Study Drugs: Ibrutinib, Daratumumab
Study Phase: Phase 2
Phase II Study of Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy
Phase II Study of Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy
Enrollment Status: Terminated
Publish Date: June 15, 2023
Intervention Type: Drug
Study Drugs: Umbralisib, Ublituximab
Study Phase: Phase 2
Phase II Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia
Phase II Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia
Enrollment Status: Completed
Publish Date: May 11, 2022
Intervention Type: Drug
Study Drug: ABT199
Study Phase: Phase 2
A Phase II Trial of Early Intervention With Acalabrutinib in Patients With CLL at High Risk for Richter's Transformation
A Phase II Trial of Early Intervention With Acalabrutinib in Patients With CLL at High Risk for Richter's Transformation
Enrollment Status: Withdrawn
Publish Date: April 05, 2022
Intervention Type: Drug
Study Drug: Acalabrutinib
Study Phase: Phase 2
A Phase 1, Open-label Study of SNX-5422 Added to Ibrutinib in Chronic Lymphocytic Leukemia Subjects With Residual Disease
A Phase 1, Open-label Study of SNX-5422 Added to Ibrutinib in Chronic Lymphocytic Leukemia Subjects With Residual Disease
Enrollment Status: Terminated
Publish Date: February 22, 2019
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1 Study of LY3039478 in Patients With Advanced or Metastatic Cancer
A Phase 1 Study of LY3039478 in Patients With Advanced or Metastatic Cancer
Enrollment Status: Completed
Publish Date: August 07, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 9 Less Clinical Trials

68 Total Publications

Co-mapping clonal and transcriptional heterogeneity in somatic evolution via GoT-Multi.
Co-mapping clonal and transcriptional heterogeneity in somatic evolution via GoT-Multi.
Journal: Cell genomics
Published: June 18, 2025
Similar Doctors
Richard R. Furman
Elite in Richter Syndrome
Dr. Richard R. Furman
Hematology | Oncology
Elite in Richter Syndrome
Dr. Richard R. Furman
Hematology | Oncology

Weill Medical College Of Cornell

520 E 70th St, Suite 651, 
New York, NY 
 (0.1 miles away)
212-746-6575
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Richard Furman is a Hematologist and an Oncologist in New York, New York. Dr. Furman is rated as an Elite provider by MediFind in the treatment of Richter Syndrome. His top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Richter Syndrome, Bone Marrow Aspiration, and Lymphadenectomy.

Distinguished in Richter Syndrome
Dr. Adam S. Kittai
Hematology | Hematology Oncology | Oncology
Distinguished in Richter Syndrome
Dr. Adam S. Kittai
Hematology | Hematology Oncology | Oncology

Icahn School Of Medicine At Mount Sinai

5 E 98th St, Suite 6, 
New York, NY 
 (1.7 miles away)
212-241-4812
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Adam Kittai is a Hematologist and a Hematologist Oncology provider in New York, New York. Dr. Kittai is rated as a Distinguished provider by MediFind in the treatment of Richter Syndrome. His top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Richter Syndrome, Small Lymphocytic Lymphoma (SLL), and Bone Marrow Aspiration. Dr. Kittai is currently accepting new patients.

Distinguished in Richter Syndrome
Dr. Kanti R. Rai
Hematology Oncology | Hematology | Oncology
Distinguished in Richter Syndrome
Dr. Kanti R. Rai
Hematology Oncology | Hematology | Oncology

North Shore Health System Medical Faculty Group Practice Inc

410 Lakeville Rd, Suite 212, 
New Hyde Park, NY 
 (13.0 miles away)
516-470-4050
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Kanti Rai is a Hematologist Oncology specialist and a Hematologist in New Hyde Park, New York. Dr. Rai is rated as a Distinguished provider by MediFind in the treatment of Richter Syndrome. His top areas of expertise are Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Leukemia, and Richter Syndrome.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Allan's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 13 Advanced Conditions
View All 54 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile